Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06814587 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Hyperpolarized 13C Pyruvate-MRI and FDG-PET in a Single Exam for the Prognosis of Ischemic Cardiomyopathy

Study acronym: FDG PET-HP MRI
StatusRecruiting
PhaseNot specified
Started2024-07-01
View on ClinicalTrials.gov ↗
This prospective, non-blinded, single-center, translational research study aims to validate a multimodal advanced imaging exam for cardiac viability. The protocol utilizes three distinct imaging modalities: Single Photon Emission Computed Tomography Myocardial Perfusion Imaging (SPECT MPI), 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), and Hyperpolarized Carbon-13 (HP-13C) Pyruvate Magnetic Resonance Imaging (MRI). Under this protocol, the SPECT MPI and FDG-PET exams will be used in combination to comprehensively assess myocardial viability. Concurrently, the HP-13C Pyruvate MRI will be utilized to provide additional insights into myocardial metabolism. The study will evaluate healthy volunteers to establish baseline parameters and patients with ischemic cardiomyopathy (ICM) before and after surgical revascularization.

Amendment history 2 changes detected by DataLookout

2026-09-15
Primary completion pushed: 2026-06-30 → 2027-06-30
2026-09-15
Completion pushed: 2026-06-30 → 2027-06-30
Trial Details
NCT Number NCT06814587
Lead Sponsor University of Texas Southwestern Medical Center
Collaborators: American Heart Association
Conditions Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
Enrollment 15 participants
Start Date 2024-07-01
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-09-14